Phase 4 trial
-
Dupixent® (dupilumab) Outperforms Xolair® (omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Patients with Asthma: First-of-its-Kind Phase 4 Head-to-Head Respiratory Trial
The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.
